HBV mutation literature information.


  Characterization of Antigen Escape Mutations in Chronic HBV-Infected Patients in Upper Egypt.
 PMID: 34234472       2021       Infection and drug resistance
8Discussion: Several other studies reported other substitutions in the ""a"" determinant region and associated with vaccine escape, such as T116N, P120S/E, I/T126A/N/I/S, Q129H/R, M133L, K141E, and D144A/E."


  Detection of Q129H Immune Escape Mutation in Apparently Healthy Hepatitis B Virus Carriers in Southwestern Nigeria.
 PMID: 34210073       2021       Viruses
Introduction: In the following years, other mutations observed on the a-determinant, which are considered as immune escape variants, including T116N, P120S/E, I/T126A/N/I/S, Q129H/R, M133L, K141E, P142S, and D144A/E, have also been reported.


  Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
 PMID: 33893696       2021       Journal of viral hepatitis
Method: K141E/I/R and G145A/R have the strongest evidence base of clinical and in vitro data to support HBV vaccine resistance, while other VEMs are considered putative, as they are supported by less robust data.
Method: We performed phylogenetic dating to estimate the times of emergence of mutations of interest, focused on RAMs V173L, L180M and M204I/V as they are best recognized to cause or contribute (individually or synergistically) resistance to 3TC, ETV and TDF, and VEMs G145A/R and K141E/I/R as they have been best described to cause HBV vaccine resistance.
Result: Vaccine escape mutations K141E/I/R was not present in our data set.


  A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants.
 PMID: 32790777       2020       PloS one
Result: It was notable that K141E and K141I, despite their difference in expression levels (i.e., anti-HA antibody signals), both bind coherently to Lenvervimab.


  In silico functional and structural characterization of hepatitis B virus PreS/S-gene in Iranian patients infected with chronic hepatitis B virus genotype D.
 PMID: 32695898       2020       Heliyon
Introduction: Also, mutations may occur in association with either vaccine-induced immune-escape (P120T, K122R, T126S, Q129H, G130N, M133L, and M133T) or in relation to the patients with occult HBV infection (Y100C, C124R, C124Y, K141E, and D144A).


  Impact of immune escape mutations and N-linked glycosylation on the secretion of hepatitis B virus virions and subviral particles: Role of the small envelope protein.
 PMID: 29604477       2018       Virology
Result: Consistent with our previous report, virion secretion was impa
Discussion: Indeed, with the Abbott Architect i2000 assay, the K141E, D144G, and G145R escape mutants as well as M133T glycosylation mutant were associated with very little HBsAg in culture supernatant.
Discussion: Of the other immune escape mutants with severely impaired virion secretion, I110M, G145R, and K141E mutants showed mild to moderate reduction in HBsAg secretion, while G119V, G130R, and C147R mutants had more or less WT efficiency of HBsAg secretion.


  Quasispecies variant of pre-S/S gene in HBV-related hepatocellular carcinoma with HBs antigen positive and occult infection.
 PMID: 29434654       2018       Infectious agents and cancer
Discussion: Several specific mutations, including G119R, C124Y, I126S, Q129R, S136P, C139R, T140I, K141E, D144A, and G145R, have been reported as being related to the decrease of HBsAg secretion.


  Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
 PMID: 29315352       2018       PloS one
Method: In addition, we looked for Vaccine Escape Mutants (VEMs) and polymorphic mutations outside (Y100C, Q101H, S117N, T118R and P120S) and within the HBsAg immuno-dominant 'a' determinant (I/T126A/N, A128V, Q129H/R, G130N, M133L/T, K141E, S143L, D144A/H/E and G145R).


  HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
 PMID: 27167598       2017       Antiviral therapy
Method: The sequences were examined for known vaccine escape mutations (sG145R/A, sP142S, sI/T126A/N/I/S, sQ129H/R, sM133L, sD144A/E, sP120S/E, sK141E, sP134I, and sT116N), immunoprophylaxis escape mutations (


  Molecular characterization of hepatitis B virus in Vietnam.
 PMID: 28859616       2017       BMC infectious diseases
4Method: The S gene sequence was analyzed for mutations in the ""a"" determinant region (T116 N, P120S/T, I/T126S/A, Q129H/R, M133 L/T, K141E, P142S, D144E, and G145R), and other virulence associated mutations (N3S, V184A, and S204R)."



Browser Board

 Co-occurred Entities




   Filtrator